Takeda Pharmaceutical’s drug soticlestat, in development for rare forms of epilepsy, did not meet main goals in Phase 3 clinical trials for both Dravet and Lennox-Gastaut syndromes. However, the drug showed some positive results in secondary measures. Takeda is continuing to analyze the data and noted that the drug was well tolerated. The drug originated in Takeda’s labs, was licensed to Ovid Therapeutics, and later brought back by Takeda. Ovid is using the funds from the deal to build a diversified drug pipeline. Takeda is exploring options for the future of soticlestat, particularly in treating Dravet syndrome.
Source link
Takeda Drug Fails Pivotal Tests in 2 Rare Epilepsies; Path Forward Depends on Regulatory Flexibility
